Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

Inclusion Criteria: * Healthy, as determined by medical history and physical examination. * Aged 4 to \< 7 years at the time of study vaccination on Day 0. * Informed consent form that has been approved by the Institutional Review Board (IRB) and signed/dated by the parent or legal guardian. * Previous documented vaccination history of 4th dose diphtheria, tetanus and acellular pertussis (DTaP) series. Exclusion Criteria: * Serious chronic disease (e.g. cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric, hematologic) * Known or suspected impairment of immunologic function * Acute medical illness with or without fever within the last 72 hours or temperature ≥ 100.4°F (≥ 38°C) at the time of enrollment * History of documented invasive meningococcal disease or previous meningococcal vaccination * Received a 5th dose vaccination with any tetanus, diphtheria or pertussis vaccine, or 4th dose of IPV prior to this study. * Received either immune globulin or other blood products within the last 3 months; or received injected or oral corticosteroids, or other immunomodulator therapy, within 6 weeks of the study vaccines. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days and individuals (e.g., asthmatics) on a short schedule of oral steroids lasting 3 to 4 days may be included in the trial as long as they have not received more than one course within the last 2 weeks prior to enrollment. * Received oral or injected antibiotic therapy within the 72 hours prior to any blood draw. * Suspected or known hypersensitivity to any of the study vaccine components, history of serious or life-threatening reaction to the trial vaccines or a vaccine containing the same substances. * Thrombocytopenia or a bleeding disorder contraindicating IM vaccination. * Unavailable for the entire study period, or unable to attend the scheduled visits or to comply with the study procedures. * Enrolled in another clinical trial. * Diagnosed with any condition, which, in the opinion of the physician investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine. * Received any other vaccine 30 days prior to the first study vaccination or scheduled to receive any vaccination during the course of the study. * Personal or family history of Guillain-Barré Syndrome (GBS).